A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

Inclusion Criteria: * Provided written informed consent * Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening * Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration that involves the trunk and/or limbs that is amenable to topical treatment with a maximum of 100 g of trial medication per week * Have a PGA of disease severity of mild or moderate on the body (trunk and/or limbs) * An mPASI score of at least 2 * Have a treatment area involving 2- 30% of the body surface area (BSA) Exclusion Criteria: * Current diagnosis of unstable forms of psoriasis * Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris * Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas * Planned exposure to either natural or artificial sunlight * History of hypersensitivity to any component of the test product or reference product * Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders * Systemic treatment with biological therapies * Use of systemic treatments that suppress the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to the baseline visit and during the trial * Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial; * Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline * Clinical signs of skin infection with bacteria, viruses, or fungi * Known Human Immunodeficiency Virus (HIV) infection * Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial